Cite this answer
CagriSema: quick citable summary
CagriSema is listed by PeptaHub as a weight loss peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “CagriSema: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/cagrisema. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/cagrisema.
What is CagriSema?
CagriSema is a Novo Nordisk fixed-dose weekly co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) at 2.4 mg each. It produced more than 20% mean weight loss in the REDEFINE 1 Phase 3 trial and is investigational, not yet FDA or EMA approved as of 2026.
Overview
CagriSema is a fixed-dose co-formulation combining cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonistreceptor agonist), both at 2.4 mg, administered as a single weekly subcutaneous injection. Developed by Novo Nordisk, it is the most effective weight-loss peptide combination in Phase 3 trials as of 2026, achieving mean body weight reductions exceeding 20% in non-diabetic adults over 68 weeks.
Mechanism of action
CagriSema harnesses two complementary appetite-regulating pathways. Semaglutide activates GLP-1 receptors in the hypothalamus, hindbrain, and vagus nerve, suppressing appetite, slowing gastric emptying, and improving insulin secretion. Cagrilintide mimics amylin, a pancreatic hormone co-secreted with insulin that acts on area postrema and nucleus tractus solitarius receptors to promote satiety, reduce food intake, and modulate glucagon secretion. The dual mechanism produces additive to synergistic appetite suppression through both hedonic and homeostatic neural pathways, which appears to underpin the superior weight loss versus either agent alone.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| weight management (investigational Phase 3 dose) | subcutaneous | 2400–2400 mcg | once weekly | Phase 3 protocol: escalate from lower doses over 16–20 weeks to target dose of 2.4 mg each component. Titration reduces GI adverse events. Investigational use only. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert CagriSema research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
REDEFINE 1 achieved a mean 20.4% weight loss (60% of participants lost at least 20%, and 23% lost 30% or more) over 68 weeks in non-diabetic adults with obesity versus 3.0% placebo. REDEFINE 2 (type 2 diabetes) showed 13.7% mean weight reduction. Both trials reported higher rates of gastrointestinal adverse events (79.6%) versus placebo (39.9%), primarily nausea, vomiting, and constipation, which were mostly transient and mild-to-moderate. Novo Nordisk filed the NDA with the FDA on December 18, 2025; regulatory decision is expected approximately October 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with CagriSema for synergistic effects.
Legal status
Not yet FDA or EMA approved as of mid-2026. Novo Nordisk filed the NDA on December 18, 2025; FDA is actively reviewing with a decision expected approximately October 2026. Semaglutide and cagrilintide are individually in various approval stages. The co-formulation remains investigational until FDA action.
Sourcing & access
Research compound
CagriSema is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
CagriSema is a fixed-dose co-formulation combining cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), both at 2.4 mg, delivered as a single weekly subcutaneous injection by Novo Nordisk.
CagriSema engages two complementary appetite pathways. Semaglutide activates GLP-1 receptors in the hypothalamus, hindbrain, and vagus nerve to suppress appetite and slow gastric emptying, while cagrilintide mimics amylin and acts on the area postrema and nucleus tractus solitarius to promote satiety.
No. As of 2026 CagriSema is not yet FDA or EMA approved. Novo Nordisk is pursuing regulatory approval following the Phase 3 REDEFINE trial data, and the co-formulation remains investigational.
REDEFINE 1 achieved a mean 20.4% weight loss (60% of participants lost at least 20%, and 23% lost 30% or more) over 68 weeks in non-diabetic adults with obesity versus 3.0% placebo. REDEFINE 2 in type 2 diabetes showed 13.7% mean weight reduction.
The Phase 3 protocol is a single weekly subcutaneous injection delivering 2.4 mg each of cagrilintide and semaglutide, titrated up from lower doses over 16 to 20 weeks to reduce gastrointestinal adverse events.
The REDEFINE trials reported gastrointestinal adverse events in 79.6% of CagriSema patients versus 39.9% on placebo, primarily nausea, vomiting, and constipation. Most events were transient and mild to moderate. Other reported effects include diarrhea, abdominal pain, injection site reactions, decreased appetite, and fatigue.
Both target weight loss through dual mechanisms, but they use different receptor pairs. Tirzepatide is a single molecule that activates GLP-1 and GIP, while CagriSema is a co-formulation of semaglutide (GLP-1) and cagrilintide (amylin). CagriSema's REDEFINE 1 weight loss of 20.4% is comparable to tirzepatide's 22.5% in SURMOUNT-1.